Daphne Simeon is a Psychiatry physician affiliated with Central Park Conservancy. OpenAlex indexes 164 publications with 7,914 citations (h-index 44); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
350 Central Park W
Suite 1b
New York, NY 100256547
Telephone
212-280-5638Registry record last updated 16 Mar 2015.
Clinical trials
- Study of Fluoxetine in Patients With Depersonalization Disorder
Sponsor: National Institute of Mental Health (NIMH)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Tricyclic Antidepressant100%Nortriptyline Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1995–2009 per NIH RePORTER. The latest:
- EFFICACY OF ZIPRASIDONE VS PLACEBO IN BORDERLINE PERSONALITY DISORDER
Icahn School of Medicine at Mount Sinai
FY2009$1,712M01RR000071 - INTRANASAL OXYTOCIN TREATMENT OF BORDERLINE PERSONALITY DISORDER
Icahn School of Medicine at Mount Sinai
FY2009$490M01RR000071 - EFFICACY OF ZIPRASIDONE VS PLACEBO IN BORDERLINE PERSONALITY DISORDER
Icahn School of Medicine at Mount Sinai
FY2008$2,854M01RR000071
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Face processing in depersonalization: An fMRI study of the unfamiliar self
Psychiatry Research Neuroimaging
2014 - A double-blind, placebo-controlled trial of topiramate for pathological gambling
The World Journal of Biological Psychiatry
2011
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”